Search

Your search keyword '"Kamiyama Toshiya"' showing total 476 results
Start Over Author "Kamiyama Toshiya" Publication Type Academic Journals
476 results on '"Kamiyama Toshiya"'

1. Artificial intelligence for surgical safety during laparoscopic gastrectomy for gastric cancer: Indication of anatomical landmarks related to postoperative pancreatic fistula using deep learning

Author

Aoyama, Yoshimasa, Matsunobu, Yusuke, Etoh, Tsuyoshi, Suzuki, Kosuke, Fujita, Shunsuke, Aiba, Takayuki, Fujishima, Hajime, Empuku, Shinichiro, Kono, Yohei, Endo, Yuichi, Ueda, Yoshitake, Shiroshita, Hidefumi, Kamiyama, Toshiya, Sugita, Takemasa, Morishima, Kenichi, Ebe, Kohei, Tokuyasu, Tatsushi, and Inomata, Masafumi

Published
2024
Full Text
View/download PDF

3. Correction: Artificial intelligence for surgical safety during laparoscopic gastrectomy for gastric cancer: Indication of anatomical landmarks related to postoperative pancreatic fistula using deep learning

Author

Aoyama, Yoshimasa, Matsunobu, Yusuke, Etoh, Tsuyoshi, Suzuki, Kosuke, Fujita, Shunsuke, Aiba, Takayuki, Fujishima, Hajime, Empuku, Shinichiro, Kono, Yohei, Endo, Yuichi, Ueda, Yoshitake, Shiroshita, Hidefumi, Kamiyama, Toshiya, Sugita, Takemasa, Morishima, Kenichi, Ebe, Kohei, Tokuyasu, Tatsushi, and Inomata, Masafumi

Published
2024
Full Text
View/download PDF

6. Development of a cross-artificial intelligence system for identifying intraoperative anatomical landmarks and surgical phases during laparoscopic cholecystectomy

Author

Fujinaga, Atsuro, Endo, Yuichi, Etoh, Tsuyoshi, Kawamura, Masahiro, Nakanuma, Hiroaki, Kawasaki, Takahide, Masuda, Takashi, Hirashita, Teijiro, Kimura, Misako, Matsunobu, Yusuke, Shinozuka, Ken’ichi, Tanaka, Yuki, Kamiyama, Toshiya, Sugita, Takemasa, Morishima, Kenichi, Ebe, Kohei, Tokuyasu, Tatsushi, and Inomata, Masafumi

Published
2023
Full Text
View/download PDF

7. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma

Author

Kamiyama Toshiya, Nakanishi Kazuaki, Yokoo Hideki, Kamachi Hirofumi, Tahara Munenori, Kakisaka Tatsuhiko, Tsuruga Yosuke, Todo Satoru, and Taketomi Akinobu

Subjects
Hepatocellular carcinoma, Hepatectomy, Early death, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Liver resection for hepatocellular carcinoma (HCC) has the highest local controllability among all local treatments and results in a good survival rate. However, the recurrence rates of HCC continue to remain high even after curative hepatectomy Moreover, it has been reported that some patients with HCC have an early death due to recurrence. We analyzed the preoperative risk factors for early cancer death. Methods Between 1997 and 2009, 521 consecutive patients who underwent hepatectomy for HCC at our center were assigned to group ED (death due to HCC recurrence or progression within 1 year after hepatectomy) and group NED (alive over 1 year after hepatectomy). Risk factors for early cancer death were analyzed. Results Group ED included 48 patients, and group NED included 473 patients. The cause of death included cancer progression (150; 78.1%), operation-related (1; 0.5%), hepatic failure (15; 7.8%), and other (26; 13.5%). Between the ED and NED groups, there were significant differences in albumin levels, Child-Pugh classifications, anatomical resections, curability, tumor numbers, tumor sizes, macroscopic vascular invasion (portal vein and hepatic vein), alpha-fetoprotein (AFP) levels, AFP-L3 levels, protein induced by vitamin K absence or antagonism factor II (PIVKA-II) levels, differentiation, microscopic portal vein invasion, microscopic hepatic vein invasion, and distant metastasis by univariate analysis. Multivariate analysis identified specific risk factors, such as AFP level > 1,000 ng/ml, tumor number ≥ 4, tumor size ≥ 5 cm, poor differentiation, and portal vein invasion. With respect to the preoperative risk factors such as AFP level, tumor number, and tumor size, 3 (1.1%) of 280 patients with no risk factors, 12 (7.8%) of 153 patients with 1 risk factor, 24 (32.9%) of 73 patients with 2 factors, and 9 (60.0%) of 15 patients with 3 risk factors died within 1 year of hepatectomy (p Conclusions Hepatectomy should be judiciously selected for patients with AFP level > 1,000 ng/ml, tumor number ≥ 4, and tumor size ≥ 5 cm, because patients with these preoperative risk factors tend to die within 1 year after hepatectomy; these patients might be better treated with other therapy.

Published
2012
Full Text
View/download PDF

8. A long-term survival case of adult undifferentiated embryonal sarcoma of liver

Author

Noguchi Keita, Yokoo Hideki, Nakanishi Kazuaki, Kakisaka Tatsuhiko, Tsuruga Yosuke, Kamachi Hirofumi, Matsushita Michiaki, and Kamiyama Toshiya

Subjects
Long-term survival, Adult undifferentiated embryonal sarcoma of liver, Curable, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Undifferentiated embryonal sarcoma of the liver (USEL) is a rare malignant hepatic tumor with a poor prognosis that is usually observed in children (aged 6 to10 years) and rarely seen in adults. We present a case of USEL in a 27-year-old woman with no previous history of the disease. Laboratory tests performed on admission showed that the patient had mildly elevated levels of aspartate aminotransferase, alanine transaminase, alkaline phosphatase, lactate dehydrogenase, and γ-glutamyl transpeptidase. The levels of viral hepatitis and tumor serum markers were all within normal limits. Computed tomography showed a large mass involving the right lobe and the medial segment of the liver. Right trisectionectomy was performed. Microscopically, the tumor was composed of pleomorphic and polynuclear dyskaryotic cells in a myxoid stroma with focal eosinophilic globules and no clear differentiation to muscle. Histological diagnosis showed undifferentiated embryonal sarcoma. Adjuvant therapy with cisplatin, vincristine, doxorubicin, cyclophosphamide, and actinomycin D was initiated. We administered a high dose of etoposide to extract the patient’s peripheral blood stem cells and performed radiation therapy and peripheral blood stem cell transplantation. At 5-year follow-up, the patient was alive without any evidence of recurrence. Here, we describe the clinical and histopathological features of USEL as well as the therapeutic options for USEL in adults with this disease.

Published
2012
Full Text
View/download PDF

9. An intraoperative artificial intelligence system identifying anatomical landmarks for laparoscopic cholecystectomy: a prospective clinical feasibility trial (J-SUMMIT-C-01)

Author

Nakanuma, Hiroaki, Endo, Yuichi, Fujinaga, Atsuro, Kawamura, Masahiro, Kawasaki, Takahide, Masuda, Takashi, Hirashita, Teijiro, Etoh, Tsuyoshi, Shinozuka, Ken’ichi, Matsunobu, Yusuke, Kamiyama, Toshiya, Ishikake, Makoto, Ebe, Kohei, Tokuyasu, Tatsushi, and Inomata, Masafumi

Published
2023
Full Text
View/download PDF

10. N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma

Author

Nakagawa Takahito, Nakanishi Kazuaki, Yokoo Hideki, Kamiyama Naoya, Hamaguchi Jun, Takahashi Masato, Nakagawa Hiroaki, Kudo Takeaki, Kamiyama Toshiya, Deguchi Kisaburo, Nishimura Shin-Ichiro, and Todo Satoru

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Correlations of disease phenotypes with glycosylation changes have been analysed intensively in the tumor biology field. Glycoforms potentially associated with carcinogenesis, tumor progression and cancer metastasis have been identified. In cancer therapy, drug resistance is a severe problem, reducing therapeutic effect of drugs and adding to patient suffering. Although multiple mechanisms likely underlie resistance of cancer cells to anticancer drugs, including overexpression of transporters, the relationship of glycans to drug resistance is not well understood. Results We established epirubicin (EPI) – and mitoxantrone (MIT) – resistant cell lines (HLE-EPI and HLE-MIT) from the human hepatocellular carcinoma cell line (HLE). HLE-EPI and HLE-MIT overexpressed transporters MDR1/ABCB1 and BCRP/ABCG2, respectively. Here we compared the glycomics of HLE-EPI and HLE-MIT cells with the parental HLE line. Core fucosylated triantennary oligosaccharides were increased in the two resistant lines. We investigated mRNA levels of glycosyltransferases synthesizing this oligosaccharide, namely, N-acetylglucosaminyltransferase (GnT)-IVa, GnT-IVb and α1,6-fucosyltransferase (α1,6-FucT), and found that α1,6-FucT was particularly overexpressed in HLE-MIT cells. In HLE-EPI cells, GnT-IVa expression was decreased, while GnT-IVb was increased. Both GnT-IVs were downregulated in HLE-MIT cells. HLE-MIT cells also showed decreases in fucosylated tetraantennary oligosaccharide, the product of GnT-V. GnT-V expression was decreased in both lines, but particularly so in HLE-MIT cells. Thus both N-glycan and glycosyltransferase expression was altered as cells acquired tolerance, suggesting novel mechanisms of drug resistance. Conclusion N-glycan and glycosyltransferase expression in HLE-EPI and HLE-MIT were analysed and presented that glycans altered according with acquired tolerance. These results suggested novel mechanisms of drug resistance.

Published
2007
Full Text
View/download PDF

17. Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors.

Author

Asahi, Yoh, Kakisaka, Tatsuhiko, Kamiyama, Toshiya, Orimo, Tatsuya, Shimada, Shingo, Nagatsu, Akihisa, Aiyama, Takeshi, Sakamoto, Yuzuru, Wakizaka, Kazuki, Shichi, Shunsuke, Kamachi, Hirofumi, and Taketomi, Akinobu

Subjects
PROTEIN-tyrosine kinase inhibitors, LIVER cancer, OVERALL survival, SURVIVAL rate, HEPATOCELLULAR carcinoma
Abstract

Aim: This study was undertaken to evaluate the outcome of curative liver resection, (LR) of Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma (BCLC‐C HCC) after tyrosine kinase inhibitors (TKIs) became approved as a treatment option for recurrent lesions. Methods: Sixty‐seven patients with BCLC‐C HCC who underwent curative LR were enrolled in this study. The patients were classified into two groups according to whether LR was performed before (n = 24) or after (n = 43) TKI approval ("beforeTKI" and "afterTKI" group, respectively). Results: There was no difference in the median disease‐free survival time after LR between the beforeTKI and afterTKI groups (5.6 and 7.1 months, respectively; p = 0.435). However, the median survival time after LR was longer in the afterTKI than beforeTKI group (42.7 and 14.9 months, respectively; p = 0.022). Univariate and multivariate analyses showed that the date of LR was the only independent factor affecting postresection survival. When the patients were limited to those with recurrence, there were no differences in the recurrence pattern or progression of HCC at the time of recurrence between the two groups. The only difference in the treatment distribution was the administration of TKIs (14 of 34 patients in afterTKI group and only 1 of 19 patients in beforeTKI group, p < 0.001). Conclusion: These data suggest that TKI therapy for recurrent BCLC‐C HCC is associated with improved overall survival. Thus, LR could be a promising option for BCLC‐C HCC in the current era of TKI therapy. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results